{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:16Z","timestamp":1787017036902,"version":"build-2736575974"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Theravance Biopharma Ireland Limited","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,6,9]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe COVID-19, supporting progression to part 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Part 2 was a randomised, double-blind phase 2 study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04402866\">NCT04402866<\/jats:ext-link>\n                      ). Hospitalised patients aged 18\u201380 years with confirmed symptomatic COVID-19 requiring supplemental oxygen (excluding baseline invasive mechanical ventilation) were randomised 1:1 to nebulised nezulcitinib 3\u2009mg or placebo for up to 7\u2009days with background standard-of-care therapy (including corticosteroids). Efficacy endpoints included respiratory failure-free (RFF) days through day 28 as the primary endpoint. Secondary endpoints included safety and change from baseline oxygen saturation (SaO2)\/fraction of inspired oxygen (FiO2) ratio on day 7, and 28-day mortality rate was a prespecified exploratory endpoint.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between June 2020 and April 2021, 205 patients were treated (nezulcitinib, 103; placebo, 102). There was no statistically significant difference between nezulcitinib versus placebo in the primary endpoint (RFF days; median, 21.0 vs 21.0; p=0.6137) or secondary efficacy endpoints. Nezulcitinib was generally well tolerated with a favourable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the prespecified primary, secondary and exploratory efficacy endpoints, including RFF through day 28, change from baseline SaO2\/FiO2 ratio on day 7, and 28-day mortality rate, were not met, nezulcitinib was generally well tolerated and had a favourable safety profile. Further studies are required to determine if treatment with nezulcitinib confers clinical benefit in specific inflammatory biomarker-defined populations of patients with COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001627","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T21:11:09Z","timestamp":1689628269000},"page":"e001627","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04402866","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John","family":"Belperio","sequence":"first","affiliation":[{"name":"Ronald Reagan UCLA Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Bogus","sequence":"additional","affiliation":[{"name":"Arensia Exploratory Medicine SRL, Chi\u0219in\u0103u, Moldova (the Republic of)"},{"name":"Timofei Mosneaga Republican Hospital, Chi\u0219in\u0103u, Moldova (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentyn","family":"Moskalenko","sequence":"additional","affiliation":[{"name":"Arensia Exploratory Medicine, LLC, Kyiv City Clinical Hospital #12, Oleksandrivska Kyiv City Clinical Hospital, Kyiv, Ukraine"},{"name":"Brovary Multidisciplinary Clinical Hospital, Brovary, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Haumann","sequence":"additional","affiliation":[{"name":"Theravance Biopharma UK Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Bourdet","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corbin G","family":"Thompson","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Woo","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund J","family":"Moran","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Saggar","sequence":"additional","affiliation":[{"name":"Theravance Biopharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2025083110465709000_10.1.e001627.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839.e4"},{"key":"2025083110465709000_10.1.e001627.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"2025083110465709000_10.1.e001627.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2025083110465709000_10.1.e001627.4","unstructured":"World Health Organization . Corticosteroids for COVID-19: living guidance. 2020. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Corticosteroids-2020.1 [Accessed 14 Apr 2020]."},{"key":"2025083110465709000_10.1.e001627.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2025083110465709000_10.1.e001627.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-981OC"},{"key":"2025083110465709000_10.1.e001627.7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of Baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025083110465709000_10.1.e001627.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2101643"},{"key":"2025083110465709000_10.1.e001627.9","unstructured":"Medicine NDo . New RECOVERY trial result: baricitinib reduces deaths in patients hospitalised with COVID-19. University of Oxford OPH, 2022."},{"key":"2025083110465709000_10.1.e001627.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01109-6"},{"key":"2025083110465709000_10.1.e001627.11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.chom.2020.05.009","article-title":"The innate immune system: fighting on the front lines or fanning the flames of COVID-19?","volume":"27","author":"McKechnie","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2025083110465709000_10.1.e001627.12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"2025083110465709000_10.1.e001627.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-016-0436-2","article-title":"Anti-inflammatory potential of Pi3K\u03b4 and JAK inhibitors in asthma patients","volume":"17","author":"Southworth","year":"2016","journal-title":"Respir Res"},{"key":"2025083110465709000_10.1.e001627.14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2021","article-title":"A phase 2 study of inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: part 1","volume":"58","author":"Singh","year":"2021","journal-title":"Eur Respir J"},{"key":"2025083110465709000_10.1.e001627.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2025083110465709000_10.1.e001627.16","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(20)30275-7","article-title":"COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study","volume":"2","author":"Manson","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025083110465709000_10.1.e001627.17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025083110465709000_10.1.e001627.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01744-X"},{"key":"2025083110465709000_10.1.e001627.19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025083110465709000_10.1.e001627.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340"},{"key":"2025083110465709000_10.1.e001627.21","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30310-6","article-title":"High-stakes heterogeneity in COVID-19","volume":"2","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025083110465709000_10.1.e001627.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with Coronavirus disease 2019 in New York City: prospective cohort study","volume":"369","author":"Petrilli","year":"2020","journal-title":"BMJ"},{"key":"2025083110465709000_10.1.e001627.23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031994"},{"key":"2025083110465709000_10.1.e001627.24","unstructured":"Lilly.com . FDA Approves OLUMIANT (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis; 2018."}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:47:07Z","timestamp":1756662427000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bmjresp-2023-001627"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001627","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}